# Study to Assess Safety and Impact of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Pain Crises

> **NCT01895361** · PHASE2 · COMPLETED · sponsor: **Reprixys Pharmaceutical Corporation** · enrollment: 198 (actual)

## Conditions studied

- Sickle Cell Disease

## Interventions

- **DRUG:** SelG1
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01895361
- **Lead sponsor:** Reprixys Pharmaceutical Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-07
- **Primary completion:** 2016-03
- **Final completion:** 2016-03
- **Target enrollment:** 198 (ACTUAL)
- **Last updated:** 2020-01-31

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01895361

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01895361, "Study to Assess Safety and Impact of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Pain Crises". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01895361. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*